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Antibiotics in Acute Bronchitis: A Meta-analysis
Stephen Bent, MD, Sanjay Saint, MD, MPH, Eric Vittinghoff, PhD, Deborah Grady, MD, MPH
PURPOSE: Most patients with acute bronchitis who seek med-
ical care are treated with antibiotics, although the effectiveness
of this intervention is uncertain. We performed a meta-analysis
of randomized, controlled trials to estimate the effectiveness of
antibiotics in the treatment of acute bronchitis.
SUBJECTS AND METHODS: English-language studies pub-
lished January 1966 to April 1998 were retrieved using
MEDLINE, bibliographies, and consultation with experts. Only
randomized trials that enrolled otherwise healthy patients with
a diagnosis of acute bronchitis, used an antibiotic in the treat-
ment group and a placebo in the control group, and provided
sufficient data to calculate an effect size were included.
RESULTS: We identified eight randomized controlled trials
that satisfied all inclusion criteria. These studies used one of
three antibiotics (erythromycin, doxycycline, trimethoprim/
sulfamethoxazole). The use of antibiotics decreased the dura-
tion of cough and sputum production by approximately one-
half day (summary effect size 0.21; 95% CI, 0.05 to 0.36). For
specific symptoms, there were nonsignificant trends favoring
the use of antibiotics: a decrease of 0.4 days of purulent sputum
(95% CI, 20.1 to 0.8), a decrease of 0.5 days of cough (95% CI,
20.1 to 1.1), and a decrease of 0.3 days lost from work (95% CI,
20.6 to 1.1).
CONCLUSION: This meta-analysis suggests a small benefit
from the use of the antibiotics erythromycin, doxycycline, or
trimethoprim/sulfamethoxazole in the treatment of acute bron-
chitis in otherwise healthy patients. As this small benefit must be
weighed against the risk of side effects and the societal cost of
increasing antibiotic resistance, we believe that the use of anti-
biotics is not justified in these patients. Am J Med. 1999;107:
62– 67. q1999 by Excerpta Medica, Inc.
Acute bronchitis is a common clinical disordercharacterized by the acute onset of cough andsputum production in a patient with no history of
chronic pulmonary disease and no evidence of pneumo-
nia or sinusitis. This definition excludes patients with
acute exacerbation of underlying pulmonary disorders,
in whom a previous meta-analysis found that antibiotic
use led to a small, statistically significant benefit (1). The
effectiveness of antibiotics in patients with acute bronchi-
tis remains uncertain, although the disorder is the tenth
most common diagnosis seen by physicians in the United
States, accounting for 10 million office visits annually (2).
The etiology of acute bronchitis is unclear. Most stud-
ies have identified viruses (adenovirus, rhinovirus, coro-
navirus, influenza, parainfluenza, respiratory syncytial
virus, and coxsackievirus) as the cause in the majority of
patients (3–14). Atypical bacteria, including Mycoplasma
pneumoniae, Chlamydia pneumoniae, and Legionella spe-
cies, have been reported to cause 5% to 25% of cases of
acute bronchitis (15–17), and typical bacteria (Streptococ-
cus pneumoniae, Haemophilus influenzae, Branhamella
catarrhalis) have been recovered from the sputum in 7%
to 44% of patients (8,18,19). However, the importance of
positive bacterial cultures from sputum is not known,
because many of these pathogens are part of the oropha-
ryngeal flora (3,9,20 –22). Recent evidence suggests that
some bronchitis in adults may be caused by Bordetella
pertussis and parapertussis, which are better known for
their role in causing whooping cough in children (23).
The majority of patients diagnosed with acute bronchi-
tis in the United States are treated with antibiotics (24 –
27). In a nationwide survey of .1,500 physicians, Gonza-
les et al (25) found that two-thirds of patients without
underlying lung disease who were diagnosed with acute
bronchitis were treated with antibiotics. In another sur-
vey, 75% of children with a diagnosis of acute bronchitis
were given a prescription for antibiotics (26).
Although antibiotics are often used in the treatment of
acute bronchitis, their efficacy is uncertain. Clinical trials
examining this issue have yielded conflicting results (28 –
37), and qualitative reviews are similarly inconclusive
(7,9,17,38,39). Widespread antibiotic use carries a sub-
stantial cost, puts patients at risk for medication side ef-
fects, and promotes antibiotic resistance.
To clarify the optimal treatment of this disorder, we
performed a meta-analysis to determine whether antibi-
otics were beneficial in patients with acute bronchitis.
Using explicit inclusion and exclusion criteria and ac-
cepted quantitative methods (40 – 42), a meta-analysis
provides summary estimates of effectiveness that may
clarify the disparate results of previous trials (43).
METHODS
Literature Review
The literature review began with a computerized
MEDLINE search using the subheading “bronchitis, drug
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therapy” and the term “xs acute disease,” and included
English-language articles published between January
1966 and April 1998. The reference lists of all retrieved
articles were scanned, and experts were consulted to iden-
tify potential trials not identified in the MEDLINE search.
Inclusion criteria consisted of the following: random-
ized trials using an antibiotic in the treatment group and
a placebo in the control group; subjects with acute bron-
chitis, no history of chronic lung disease, and pneumonia
excluded by chest radiograph or clinical exam; therapy
for at least 5 days; and the presentation of sufficient data
to calculate the difference in efficacy between the treat-
ment and the placebo as a continuous variable. Studies
were excluded if they were nonexperimental in design or
if they compared one antibiotic with another without a
placebo arm.
For each study, two authors independently abstracted
the author, journal title, year of publication, sample size,
average age of subjects, antibiotic regimen used, major
outcome measure(s), and the inclusion and exclusion cri-
teria. Discrepancies in the abstracted data were resolved
by consensus.
Analysis
The eight eligible studies did not use a common outcome
measure. When several outcomes were available from
one study, we chose “days of sputum production” as the
main outcome, because this symptom is most character-
istic of the disease (4). For studies that did not include the
outcome “days of sputum production,” we chose the out-
come in the study that was the most clinically similar
(sputum production score, cough amount score). We
transformed each outcome into units of standard devia-
tion, thus giving a comparable effect size for different
outcomes. The study-specific effect size was the differ-
ence in the mean outcome for the antibiotic and placebo
groups, divided by the pooled standard deviation of the
outcome measure in that study. The summary effect size
across studies was calculated as a weighted average of the
study-specific effect sizes, with weights equal to the in-
verse of the estimated variance. The significance of the
summary effect size, standardized by its estimated vari-
ance, was assessed by comparing it with the standard nor-
mal distribution. A test for heterogeneity was calculated
by comparing the weighted average of the squared differ-
ences between summary and study-specific effect sizes
with an appropriate X2 distribution, with the same
weights being used. These calculations used standard for-
mulas (44), which assume that the outcomes are nor-
mally distributed and the sample sizes are approximately
equal in the antibiotic and placebo groups.
We also calculated summary mean differences for all
outcomes reported by four or more studies. The sum-
mary measure was the weighted average of the difference
between the antibiotic and placebo groups in the mean
outcome measure for each study. Weights were given by
the inverse of the variance of each mean difference, esti-
mated using the pooled standard deviation for each
study. Tests of the significance of the observed summary
mean differences and of heterogeneity were also per-
formed (44).
We examined the potential for publication bias using
the correlation between the number of subjects and the
effect size in each study. If small studies with negative
results were less likely to be published, then the correla-
tion between number of subjects and effect size would be
large. If there was not any publication bias, then there
should not be a significant correlation between the num-
ber of subjects and the effect size.
RESULTS
Our search identified 203 reports, including 10 random-
ized, placebo-controlled trials of antibiotics for the treat-
ment of acute bronchitis (28 –37). Two (28,31) of these
studies had to be excluded because insufficient data were
presented in the original articles, and attempts to retrieve
the necessary data from the authors were unsuccessful.
The remaining eight trials, all of which used one of three
antibiotics (erythromycin, doxycycline, trimethoprim/
sulfamethoxazole), were included in the meta-analysis.
Reasons for exclusion are listed in Table 1. The character-
istics of the 10 randomized controlled trials, including the
two that were excluded because of insufficient data, are
shown in Table 2.
The overall summary effect size was 0.21 (95% CI, 0.05
to 0.36) indicating a small (about one-fifth of a standard
deviation), statistically significant benefit from the use of
antibiotics (Figure), equivalent to approximately one half
day less of cough and sputum production.
Three outcomes were reported by at least four studies
(Table 3). Although each of these results favor antibiotics,
none was statistically significant. For days of purulent
Table 1. Reasons for Exclusion of Reports Retrieved from Lit-
erature Search
Reason for Exclusion
Number
of Reports
Not original data 74
No control group 87
Main intervention was not antibiotic therapy 16
Patients with COPD were included 11
Main intervention was prophylaxis 1
Subjects had another infectious disorder
(sinusitis, bronchiolitis)
4
Insufficient data presented 2
Total excluded 195
COPD 5 chronic obstructive pulmonary disease.
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sputum, the summary mean difference was 0.4 (95% CI,
20.1 to 0.8); the mean difference was 0.5 (95% CI, 20.1
to 1.1) for days of cough and 0.3 (95% CI, 20.6 to 1.1) for
days lost from work. The effect of antibiotic treatment on
days lost from work was very small, and unlike days of
cough and sputum production, did not approach statis-
tical significance.
A test for heterogeneity was not significant for the
overall summary effect size (P 5 0.37) or for days of spu-
tum production (P 5 0.50), suggesting that these results
are homogenous and can be combined. A test for heter-
ogeneity was significant for the summary mean difference
for days lost from work (P 5 0.03) and days of cough
Table 2. Randomized Trials of Antibiotics in Acute Bronchitis
First Author, Year
(reference)
No. of
Subjects Antibiotic
Main Outcome
Measure
Study Result
(95% CI)*
Standardized Effect
Size (95% CI)†
Howie, 1970 (31) 836 Demethyl-chlortetracycline Average days of
purulent spit
0.3‡ Not available‡
Stott, 1976 (33) 207 Doxycycline Days of yellow spit 0.6 (20.2 to 1.4) 0.20 (20.08 to 0.48)
Franks, 1984 (30) 54 Trimethoprim/sulfamethoxazole Cough amount score 0.2 (20.2 to 0.6)§ 0.25 (20.30 to 0.79)
Williamson, 1984
(34)
69 Doxycycline Days of purulent
sputum
20.2 (21.2 to 0.8) 20.09 (20.57 to 0.38)
Brickfield, 1986
(28)
50 Erythromycin Sputum production
score
0.2‡¶ Not available‡
Dunlay, 1987 (29) 45 Erythromycin Sputum production
score on day 10
0.5 (0.1 to 0.9)# 0.80 (0.20 to 1.41)
Scherl, 1987 (32) 31 Doxycycline Days of sputum 1.9 (20.2 to 4.0) 0.64 (20.08 to 1.36)
Verheij, 1994 (35) 140 Doxycycline Days of productive
cough
0.5 (20.4 to 1.4) 0.18 (20.15 to 0.52)
Hueston, 1994
(36)
23 Erythromycin Days of productive
cough
20.4 (22.4 to 1.6) 20.21 (21.14 to 0.72)
King, 1996 (37) 91 Erythromycin Days of sputum
production
0.7 (21.3 to 2.7) 0.14 (20.27 to 0.55)
* Result is the mean in the antibiotic group minus the mean in the placebo group for the main outcome measure. A positive result indicates a benefit
from antibiotics. A negative result indicates a benefit from placebo.
† Effect size is the difference between the mean outcome in the antibiotic and placebo groups divided by the pooled standard deviation.
‡ These studies did not provide data that allowed calculation of a confidence interval or a continuous outcome measure, and therefore could not be
included in the overall summary effect size.
§ Cough amount score was a patient-reported score on a severity scale of 1 to 3.
¶ Sputum production score was a patient-reported score on a severity scale of 1 to 4.
# Sputum production score was a patient-reported score on a severity scale of 1 to 5.
CI 5 confidence interval.
Figure. Effect sizes and summary overall estimate. Effect size is
the difference between the mean outcome in the antibiotic and
placebo groups divided by the pooled standard deviation. Hor-
izontal lines denote 95% confidence intervals. Dots represent
point estimates.
Table 3. Summary Mean Differences between Antibiotic and
Placebo Groups
Outcome Measure
(reference)
Summary Mean
Difference (95% CI)*
Days of purulent sputum (6 trials)
(32–37)
0.4 days (20.1–0.8)
Days of cough (4 trials) (32–35) 0.5 days (20.1–1.1)†
Time off work (6 trials) (32–37) 0.3 days (20.6–1.1)†
* Summary mean difference is the weighted average of the difference
between the antibiotic and placebo groups in the mean outcome mea-
sure for each study.
† A test of heterogeneity was statistically significant.
CI 5 confidence interval.
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(P 5 0.05), suggesting that these outcomes may have
been derived from studies that used different methods.
There was no correlation between study size and overall
effect size (r 5 20.13, P 5 0.75).
DISCUSSION
Randomized controlled trials evaluating the efficacy of
antibiotics in acute bronchitis have had inconsistent re-
sults. Of the eight trials included in our meta-analysis,
four showed no benefit from the use of antibiotics (32–
34,36), whereas four reported a benefit (29,30,35,37).
Part of the discrepancy may be because studies used dif-
ferent outcome measures, some of which are of uncertain
clinical importance. For example, the outcome measures
in one trial that reported a statistically significant benefit
from antibiotics included a reduction in mean tempera-
ture from 37.38C to 36.98C and a reduction in the use of
antihistamines (30).
Because the published trials used several outcome
measures, we used the standardized effect size, expressed
in units of standard deviation, to quantitate the overall
effect of antibiotic therapy. We chose the outcome that is
most characteristic of acute bronchitis (days of sputum
production) in the six studies where it was available, and
we used the most similar outcome in the two other stud-
ies (cough amount score, sputum production score). We
found a small, statistically significant benefit to the use of
antibiotics in patients with acute bronchitis approxi-
mately equal to one-fifth of a standard deviation unit. To
relate the observed benefit in the summary effect size to
clinical variables, we also calculated summary mean dif-
ferences for all outcomes that were reported by at least
four trials (duration of sputum production, duration of
cough, and days lost from work), all of which showed
small, nonsignificant trends favoring the use of antibiot-
ics. Our meta-analysis suggests that patients with acute
bronchitis who are treated with antibiotics have a reduc-
tion in the duration of cough and sputum production of
approximately one half day.
Our results should be interpreted with caution. As with
all meta-analyses, we assumed that the individual trials
are sufficiently similar to provide a meaningful summary.
The studies did have several important differences. They
took place in different geographic locations, used three
different antibiotics (erythromycin, doxycycline, tri-
methoprim/sulfamethoxazole), and were conducted
during a 20-year period. However, despite these differ-
ences, statistical tests for heterogeneity did not show dif-
ferences between studies for the main outcome, or for the
outcome of sputum production. Although different anti-
biotics were used, all groups were treated for at least 5
days, and the spectrum of organisms covered by the var-
ious antibiotics was similar.
We identified 10 randomized controlled trials in our
literature review. Results from two of these trials could
not be included because insufficient data were reported
(28,31). Both of these trials showed no benefit from the
use of antibiotics. Thus, their exclusion tended to bias our
results in favor of antibiotics. In addition, the summary
effect size may have been overestimated if publication
bias made it more likely that studies showing benefit were
published, whereas those showing no benefit were not. If
there was publication bias, small studies with negative
findings should have been unlikely to be published,
whereas small studies with positive findings should have
been more likely to be published, leading to a correlation
between study size and effect size. We found no such
correlation.
We used similar methodology to an earlier meta-anal-
ysis that examined the effect of antibiotics in patients with
acute exacerbations of chronic obstructive pulmonary
disease (1). That study reported a summary effect size of
0.22 (95% CI, 0.10 to 0.34), also indicating a small, sta-
tistically significant benefit from the use of antibiotics.
Patients who were treated with antibiotics had a modest
improvement in peak expiratory flow of approximately
11 L/min compared with those treated with placebo. Al-
though the magnitude of benefit from antibiotic treat-
ment in that meta-analysis is similar to that in the current
meta-analysis, such a benefit may be more important for
a patient with underlying lung disease who has less func-
tional reserve.
The costs of widespread antibiotic use are great for
both patients and society. They include prescription
costs, medication side effects, and an increase in antibi-
otic resistance. Several studies have shown that wide-
spread antibiotic use leads to the development of resistant
organisms (45– 47). Antibiotic use for acute bronchitis
constitutes a substantial portion of all antibiotic use in the
United States, accounting for 9% of all prescriptions writ-
ten for children (26). Furthermore, side effects of antibi-
otics used for acute bronchitis are common, occurring in
10% to 36% of patients (28 –31,33,35,37). The practice of
routinely giving antibiotics for acute bronchitis encour-
ages patients to expect antibiotics for subsequent epi-
sodes (48), which adds to the cycle of medication costs,
side effects, and antibiotic resistance. We believe that
there should be a clear, substantial benefit to antibiotics
to justify these costs.
Some authors have suggested that certain subgroups of
patients with acute bronchitis may benefit from antibiot-
ics (9,35,39). In a study of 140 patients randomly assigned
to treatment with doxycycline or placebo, Verheij et al
(35) reported that doxycycline resulted in clinical benefit
among patients older than 55 years and in those who felt
ill at study entry. However, approximately 30% of the
patients in that study had abnormalities on lung auscul-
tation and therefore may have had conditions such as
Antibiotics in Acute Bronchitis/Bent et al
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pneumonia that would show a large benefit from antibi-
otic treatment (49). Others have suggested treating pa-
tients who test positive for Mycoplasma pneumoniae or
Chlamydia pneumoniae (39), although there is no evi-
dence from randomized trials to support this practice. In
a randomized trial using erythromycin to treat acute
bronchitis, King et al (37) found no difference in out-
comes between patients who tested positive and those
who tested negative for Mycoplasma pneumoniae. More
research is needed to determine if there are subgroups of
patients who are likely to have a substantial benefit from
treatment with antibiotics.
The studies included in this meta-analysis examined
the effect of one of three different antibiotics (erythromy-
cin, doxycycline, trimethoprim/sulfamethoxazole). None
of the studies used one of the newer macrolide or floro-
quinolone antibiotics. We are not aware of any random-
ized, placebo-controlled trials of these agents in adults
with acute bronchitis. Future studies should determine
the risks and benefits associated with use of these newer
antibiotics.
In summary, we found a statistically significant benefit
from the use of antibiotics in acute bronchitis. Treatment
reduced the duration of cough and sputum production
by approximately one half day. The decision to use anti-
biotics for the treatment of adults with acute bronchitis
must be weighed against the costs associated with wide-
spread use of these agents. In healthy patients with acute
bronchitis who have no evidence of chronic pulmonary
disease, we believe that the small benefit associated with
antibiotic treatment does not outweigh the risk of side
effects and the increase in antibiotic resistance.
Note Added in Proof: After this paper was submitted, a
meta-analysis on a similar topic was published: Smucny
JJ, Becker LA, Glazier RH, McIsaac W. Are antibiotics
effective treatment for acute bronchitis? A meta-analysis.
J Fam Pract. 1998;47:453– 460.
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